• Manufacturing Human Vaccines

 Human vaccine production line with more than 3500 square meters of clean rooms and advanced equipments has the annual capacity of producing more than 20 million doses of human vaccines on the basis of GMP requirements and also WHO standards. Currently seasonal trivalent and quadrivalent are considered as the main products in vaccine production line.

• Seasonal Influenza vaccine ( FluPak®)

 Seasonal human Influenza vaccine, FluPak® is the first product of Bayerpaul Group that manufactured under GMP standards and  has approval of  Iranian NRA under supervision of WHO. FluPak®  is an egg base inactivated split virion vaccine without thiomersal, which presented in single dose form in prefilled syringe 0.5 ml. and  present in market since 2017.

• Quadrivalent Influenza vaccine (Quadrivalent -FluPak®)

The quadrivalent flu vaccine is designed to protect against four different flu viruses; two influenza A viruses and two influenza B viruses. Quadrivalent seasonal human Influenza vaccine (Quadrivalent-FluPak® ( is manufactured under GMP standards and  has approval of  Iranian NRA under supervision of WHO. Quadrivalent-FluPak® is an egg base inactivated split virion vaccine without thiomersal, which presented in single dose form in prefilled syringe 0.5 ml. and  present in market since 2018.

• Measles, Mumps, and Rubella vaccine (MMR-Pak®)

  • MMR-Pak® (Measles, Mumps, and Rubella Virus Vaccine Live) is an immunization vaccine against measles, mumps, and rubella diseases. It is a mixture of live attenuated viruses of the three viruses, which is manufactured under GMP standards and  has approval of  Iranian NRA. The MMR-Pak® presented in single dose and Multi doses form in vial and  present in market since 2018.
  • To reconstitute, use only the diluent supplied, Administration for MMR-Pak® Single Dose Vial. Withdraw the entire volume of diluent into the syringe to be used for reconstitution.

• Inactivated Poliomyelitis Vaccine IPV, PolioPak®

PolioPak® (Inactivated Poliomyelitis Vaccine) consists of inactivated (killed) poliovirus strains of all three poliovirus types. PolioPak® is given by intramuscular injection. The inactivated polio vaccine produces antibodies in the blood to all three types of poliovirus. In the event of infection, these antibodies prevent the spread of the virus to the central nervous system and protect against paralysis.  PolioPak® (Inactivated Poliomyelitis Vaccine) will present in market from 2019.